(Q38848054)

English

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia

scientific article published on 7 April 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

Giorgia Battipaglia

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Annalisa Ruggeri

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

Jean El Cheikh

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Matthieu Jestin

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Ahmad Antar

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Syed Osman Ahmed

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Walid Rasheed

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Marwan Shaheen

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Ramdane Belhocine

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Eolia Brissot

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Remy Dulery

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sandra Eder

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Federica Giannotti

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Francoise Isnard

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Simona Lapusan

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Marie-Therese Rubio

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Anne Vekhoff

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Mahmoud Aljurf

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Ollivier Legrand

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Mohamad Mohty

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

language of work or name

0 references

publication date

7 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

7 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

123

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

2867-2874

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Phase I study of sorafenib in patients with refractory or relapsed acute leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

The roles of FLT3 in hematopoiesis and leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

21 January 2018

FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.30680

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.30680

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28387928%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38848054&oldid=1790207496"